Pomerantz Law Firm Investigates SELLAS Life Sciences Group for Potential Securities Fraud
The law firm of Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) and certain officers or directors on behalf of investors. The investigation follows a report that the company's phase 3 clinical trial for Galinpepimut-S reached its pre-specified endpoint of 80 patient deaths but had not yet released results as of August 28, 2026. On this news, SELLAS' stock price dropped by $2.00 per share (13.15%) to close at $13.21 on the same day. The firm is inviting investors who may have been affected to contact its legal team for more information about joining a potential class action. Pomerantz LLP, known as one of the leading firms in securities litigation and with offices across multiple global cities, has a long history of pursuing cases involving corporate misconduct.
Tickers: $SLS
Topics: clinical_trials legal stock_price_drop